Comment from Nuvation Bio

Summary: David Hung, CEO of Nuvation Bio, supports the petition to update FDA immunotherapy labeling to exclude patients with ROS1 and RET rearrangements from first-line treatment. He argues that these updates are necessary to ensure patients receive targeted therapies that are more effective and safer than immunotherapy for these specific genetic mutations.